Abbott profit jumps on Covid testing demand, strong medical device sales
ABBOTT Laboratories reported a rise in quarterly profit on Wednesday (Apr 20) helped by strong demand for its Covid-19 tests and a rebound in medical device sales.
Abbott, which provides Covid-19 testing kits and facilities, benefited from a surge in testing demand as cases of the highly transmissible Omicron variant in the United States reached record levels in January.
Still, the company left its full-year adjusted earnings forecast unchanged.
Covid-19 test kits brought in revenue of US$3.3 billion in the quarter, boosting total sales at its diagnostics business, which grew 31.7 per cent on a reported basis.
A rebound in demand for elective procedures boosted sales of medical devices as coronavirus cases dropped in the latter half of the quarter.
Abbott now forecast US$4.5 billion in Covid-19 testing sales this year, which it expects will occur largely in the first half of the year.
The Illinois-based company reiterated that it expects 2022 adjusted profit per share to be at least US$4.70. REUTERS
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Australia’s retail sales volumes fall 0.4% in Q1
Possible class action lawsuit against Cordlife by customers could take at least 2 years
Chinese tariffs could leave cognac makers with too much brandy
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore